Endpoints News

AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial

Published

2 weeks ago

on

New clinical trial data on the in vivo CAR-T therapy that AstraZeneca acquired last year suggest that while the experimental treatment can curb multiple myeloma in some patients, it may not be safer than the …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version